HCA Healthcare, Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +28

HCA Healthcare Reports First Quarter 2026 Results

AI-generated analysis

πŸ“ˆ Revenue grew 4.3% year-over-year to $19.109 billion in Q1 2026.

πŸ’° Net income increased 0.6% to $1.620 billion, with EPS rising 10.9% to $7.15.

πŸ“‰ Adjusted EBITDA grew 1.9% to $3.802 billion as a key non-GAAP financial metric.

πŸ’§ Operating cash flow surged 22.0% year-over-year to reach $2.014 billion.

πŸ₯ Same facility admissions rose modestly, with equivalent admissions up 1.3%.

⚠️ Respiratory-related activity suppressed volume, causing a notable 42% drop in respiratory admissions.

❄️ A winter storm in January negatively impacted volumes in specific markets during the quarter.

πŸ“Š Same facility revenue per equivalent admission increased 3.1% despite lower surgery volumes.

πŸ’Έ The company repurchased 3.157 million shares for a total cost of $1.571 billion.

🏦 Total debt stands at $48.023 billion against total assets of $61.450 billion as of March 31, 2026.

πŸ’Ή Board declared a quarterly cash dividend of $0.78 per share payable June 30, 2026.

πŸ”„ Q1 2026 results showed unfavorable volume impacts mostly offset by recognition of certain Medicaid supplemental programs.

πŸ“… Management reaffirmed its full-year 2026 estimated guidance ranges previously issued in January.

βš–οΈ Earnings are subject to risks including health care public policy developments and economic conditions like inflation.

Bullish Signals
  • Revenues increased 4.3 percent to $19.109 billion, demonstrating continued top-line growth.
  • Diluted earnings per share grew significantly by 10.9 percent to $7.15 per diluted share.
  • Cash flows from operating activities surged 22.0 percent to $2.014 billion, highlighting strong liquidity generation.
  • Same facility equivalent admissions increased 1.3 percent, indicating underlying demand resilience.
  • The company repurchased 3.157 million shares at a cost of $1.571 billion and maintains $9.179 billion in remaining repurchase authorization.
  • HCA Healthcare declared a quarterly cash dividend of $0.78 per share to be paid on June 30, 2026.
  • The company reaffirmed its 2026 estimated guidance, signaling management confidence in future performance despite headwinds.
  • Unfavorable volume impacts were successfully offset by the recognition of certain Medicaid supplemental programs not included in initial guidance.
Risk Factors
  • During the first quarter of 2026, HCA Healthcare did not experience a typical seasonal volume increase due to respiratory activity, with respiratory-related admissions dropping 42% and emergency room visits down 32% compared to the prior year.
  • A winter storm in January negatively impacted first quarter volumes in certain markets, further depressing operational metrics during the reporting period.
  • Same facility inpatient surgeries declined 0.3% while same facility outpatient surgeries declined 1.7%, indicating headwinds in elective or procedure-based care volumes despite overall revenue growth.
  • The company's forward-looking guidance explicitly excludes significant potential risks such as legal claims costs, impairment of long-lived assets, and losses on debt retirement or sales of facilities, introducing uncertainty to future earnings stability.
  • Future dividend payments are subject to Board discretion and depend on financial condition rather than being guaranteed, suggesting a lack of committed cash distribution beyond the current quarter.
  • Guidance assumptions rely on an anticipated mostly stable operating environment and stable payer mix, which could be disrupted by health care public policy developments or administrative reforms.
  • The expiration of enhanced premium tax credits and estimated impacts from administrative reforms are factored into guidance but present external regulatory headwinds that could alter reimbursement dynamics.
Full Analysis
HCA Healthcare reported strong financial performance for the first quarter ended March 31, 2026, with revenues increasing 4.3% year-over-year to $19.109 billion and net income attributable to HCA rising 0.6% to $1.620 billion. Earnings per share and adjusted earnings per share both grew significantly by 10.9% to $7.15 per diluted share, while adjusted EBITDA increased 1.9% to $3.802 billion. Cash flows from operating activities saw a notable 22.0% jump to $2.014 billion, reflecting improved liquidity relative to the previous year's $1.651 billion. Operational metrics showed resilience despite seasonal headwinds, with same facility admissions up 0.9% and equivalent admissions up 1.3%. However, volumes were impacted by lower respiratory-related activity, which was down 42% in this period, partly due to reduced winter illness and a January winter storm affecting certain markets. Surgical volumes declined slightly, with inpatient surgeries down 0.3% and outpatient procedures falling 1.7%, but revenue per equivalent admission rose 3.1% to offset volume changes. The company repurchased over 3 million shares for $1.571 billion during the quarter, maintaining a remaining authorization of $9.179 billion. Looking ahead, HCA Healthcare reaffirmed its full-year 2026 guidance previously issued in January. The board declared a quarterly cash dividend of $0.78 per share, payable on June 30, 2026, to shareholders of record as of June 16, 2026. CEO Sam Hazen highlighted the company’s adaptability in dynamic conditions, and CFO discussions noted that unfavorable respiratory volume impacts were largely offset by newly recognized Medicaid supplemental programs not included in initial guidance. The balance sheet remains robust with $940 million in cash equivalents and $48.023 billion in total debt.